Lytix Biopharma: Invitation to Q3 2025 Results Presentation

14 Nov 2025 07:00 CET

Oslo, Norway, November 14, 2025 – Lytix Biopharma AS (“Lytix” or the “Company”)
will release its third quarter 2025 financial results on Tuesday, November 18th,
2025.

Join us for a live webcast presentation featuring CEO Øystein Rekdal and CFO
Gjest Breistein, where they will discuss the results and provide key insights.

Date: Tuesday, November 18th, 2025
Time: 10:00 AM CET

Q&A Session:
We welcome your questions in advance. Please send them to
post@lytixbiopharma.com, and they will be addressed during the Q&A session
following the presentation.

Webcast Details:
The presentation and Q&A session will be conducted in English. You can view the
live event by registering here:
https://channel.royalcast.com/landingpage/hegnarmedia/20251118_1/

Missed the Live Session?
A recording of the presentation will be available shortly after the event on our
financial reports page: https://www.lytixbiopharma.com/financial-reports

For more information, please contact:
Gjest Breistein, CFO
+47 952 60 512
gjest.breistein@lytixbiopharma.com

About Lytix:
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly differentiated oncolytic molecule platform based on world-leading
research in host-defense peptide-derived molecules. Lytix Biopharma’s lead
product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule
representing a new approach to maintaining durable anti-cancer immunity. Lytix
Biopharma has a pipeline of molecules that work across multiple cancer
indications and treatment settings, both as mono- and combination therapy. Lytix
is listed on Euronext Growth Oslo under the ticker LYTIX.
For more information, visit www.lytixbiopharma.com.

More information:
Access the news on Oslo Bors NewsWeb site

659688_Lytix Biopharma - Invitation to Q3 Presentation.pdf